A Single-center Pilot Study Evaluating a Preemptive Short Course of Glecaprevir/Pibrentasvir in Hepatitis C Positive to Negative Kidney Transplantation

The purpose of this research study is to evaluate the feasibility of a 2 week course of glecaprevir/pibrentasvir (Mavyret) starting immediately prior to transplantation to treat hepatitis C virus (HCV) in kidney transplant recipients who receive a kidney from a donor with HCV.

Study Overview

• Status: Active, not recruiting
• Conditions: ESRD
• Intervention / Treatment: Drug: Glecaprevir/pibrentasvir

Detailed Description

This is a prospective, open-label, single-center, pilot study. The patient population will include 20 patients who are on the kidney transplant waitlist at NYU Langone Health, are hepatitis C virus (HCV) negative, are willing to accept an organ from an HCV positive donor, and consent to participate in this trial. Study subjects will receive a kidney transplant from a deceased donor who tested positive for HCV as confirmed by nucleic acid amplification testing (NAT) per standard of care. All study subjects will receive a two week course of preemptive therapy with glecaprevir/pibrentasvir (Mavyret®), starting on postoperative day (POD) 0 prior to the transplant. If HCV RNA is undetectable after 2 weeks of therapy, Mavyret will be discontinued and study subjects will be followed with an intensive HCV monitoring protocol. If HCV RNA is detectable after 2 weeks of therapy, Mavyret will be continued to complete a full course of 8 weeks per standard of care. All patients will undergo close monitoring and surveillance for HCV viremia post-transplant to ensure that sustained virologic response (SVR) is achieved.

• Study Type: Interventional
• Enrollment (Actual): 20
• Phase: Early Phase 1

Contacts and Locations

Study Locations

• United States
  • New York
    • New York, New York, United States, 10016
      • NYU Langone Health

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 99 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• At least 18 years of age
• Listed for kidney transplantation at NYU Langone Health and willing to accept HCV positive donor organs
• Able to complete routine post-transplant visits and study visits for a minimum of 1 year after transplantation
• Women of childbearing potential must agree to use birth control in accordance with Mycophenolate Risk Evaluation and Mitigation Stategy (REMS) after transplant due to increased risk of birth defects and/or miscarriage
• Both men and women must agree to use at least one barrier method of contraception after transplant to prevent any secretion exchange
• Able and willing to provide informed consent
• Receive an organ offer for a kidney from a deceased donor that:
• Is HCV NAT positive
• Meets all standard criteria for organ acceptability at NYU Langone Transplant Institute

Exclusion Criteria:

• HCV RNA positive or history of previously treated HCV
• Evidence of active hepatitis B infection or on active antiviral treatment of HBV
• HIV positivity
• Pregnant or nursing (lactacting) women
• Current use of atazanavir or rifampin
• Known hypersensitivity to glecaprevir and/or pibrentasvir
• Current or history of decompensated liver disease
• Recipients of dual organs (i.e. simultaneous liver and kidney transplant, simultaneous kidney and pancreas transplant, or simultaneous heart and kidney transplant)
• Receive an organ offer for a kidney from a deceased donor that is:
• Confirmed HIV positive
• Confirmed HBV positive (positive hepatitis B surface antigen, and/or detectable hepatitis B virus DNA)
• Known to have previously failed DAA therapy for treatment for HCV
• HCV antibody positive, but NAT negative

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Study group; All study subjects will receive glecaprevir/pibrentasvir (Mavyret®) 300/120 mg orally x 14 days, starting on POD 0 prior to transplantation of the HCV positive kidney. If HCV RNA is detectable after 2 weeks of therapy, Mavyret® will be continued to complete a full course of 8 weeks per standard of care. Safety monitoring and frequent surveillance for HCV viremia will occur for all subjects throughout the duration of the study. The kidney transplantation procedure and routine post-transplant management will be performed per standard of care.

Drug: Glecaprevir/pibrentasvir; Manufacturer is AbbVie, Inc., North Chicago, IL Mavyret® is commercially available and FDA approved for the treatment of HCV genotype 1, 2, 3, 4, 5, or 6 infection in patients without cirrhosis or with compensated cirrhosis and also for the treatment of adult patients with HCV genotype 1 infection who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor. An immediate release bilayer oral tablet containing a fixed-dose combination of 100 mg of glecaprevir and 40 mg of pibrentasvir. The daily dose of glecaprevir/pibrentasvir used will be the standard FDA approved dose: 3 tablets taken once daily (total daily dose: glecaprevir 300 mg and pibrentasvir 120 mg).; Other Names: Mavyret

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in the Percentage of Incidence of sustained clearance of HCV (cure) 12 weeks after treatment of viremia	Measured in percentage of patients with SVR after treatment for HCV after kidney transplant. SVR will be defined as the absence of detectable HCV RNA Quantitative (PCR) testing 12 weeks after the completion of the treatment course.	Visit 2 (Day 1) , Visit 3 (Day 3) , Visit 4 (Day 7), Visit 5 (Day 13), Visit 16 (Day 365)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Overall patient and graft survival at 1 year post-transplant	Patients will have regular follow-up as standard-of-care for all kidney transplant recipients. Patients' survival will be readily apparent. Furthermore, all deaths of transplant recipients and allograft losses within the first year of transplant are required to be reported to UNOS. Survival rates will be reported as a percentage.	Visit 1 (Day 0), Visit 16 (Day 365)
Change in the Allograft function	This parameter is being used to measure overall graft function and will be described using the median value at 1 year post transplant for the cohort. All transplant recipients will have regular follow-up as standard-of-care and eGFR will be calculated using the MDRD equation.	Visit 1 (Day 0), Visit 16 (Day 365)
Percentage of Incidence and grade of biopsy-proven rejection	All transplant recipients will have regular follow-up as routine clinical care and as such, will receive for cause biopsies per standard of care if there is a clinical suspicion of rejection. Biopsies will be read by a renal pathologist per standard of care and reported in the EPIC system. The incidence of rejection will be calculated as a percentage of the patients with diagnosed rejection on biopsy within 1 year of transplant.	Visit 1 (Day 0), Visit 16 (Day 365)
Time course to transplantation (median)	Time to transplantation will be measured from the time of listing (recorded in EPIC) to time of transplant and also time from written acknowledgment of willingness to participate in the trial to time of transplant.	Screening vist, Visit 1 (Day 0)
Percentage of Incidence HCV viremia post-transplant and after 2 weeks of treatment	Measuring serial HCV RNA Quantitative (PCR) starting immediately after transplant and continued throughout the duration of the study. A patient will be considered to be viremic when a post-transplant HCV RNA Quantitative (PCR) test is positive. The incidence of viremia after transplant will be calculated as the percent of the patients transplanted with an HCV-positive donor who subsequently developed HCV viremia (detected by RNA Quantitative (PCR) testing). The incidence of viremia after two weeks of treatment will be calculated as the percentage of the patients with detectable HCV viremia (detected by RNA Quantitative (PCR) testing) after completing 2 weeks of treatment with glecaprevir/pibrentasvir and therefore require continuation of therapy to complete an 8 week course	Visit 1 (Day 0), Visit 5 (Day 13), Visit 16 (Day 365)
Time course of exposure to development of clinically detectable viremia in those who develop viremia	Measuring serial HCV RNA Quantitative (PCR) starting immediately after transplant and continued throughout the duration of the study to find the median time to viremia with standard deviations. If the HCV RNA Quantitative (PCR) test is positive at any time point, we will calculate the time from transplant to detectable HCV RNA Quantitative (PCR).	Visit 1 (Day 0) to Visit 16 (Days 364)
Time course of clearance of viremia after treatment initiation	Measuring serial HCV RNA Quantitative (PCR) starting immediately after transplant and continued throughout the duration of the study to find the median time to clearance with standard deviations. If the HCV RNA Quantitative (PCR) test is positive at any time point, we will calculate the time to documented clearance as indicated by an undetectable HCV RNA Quantitative (PCR),	Visit 1 (Day 0) to Visit 16 (Days 364)
Percentage of Incidence of treatment failure/treatment resistant strains of HCV	If SVR12 is not achieved with either a 2 week or 8 week course of glecaprevir/pibrentasvir, it will be considered a treatment failure and resistance testing will be performed. The incidence will be reported as a percentage.	Visit 1 (Day 0), Visit 5 (Day 13), Visit 9 (Day 56)

Collaborators and Investigators

• Sponsor: NYU Langone Health
• Investigators: Principal Investigator: Bonnie Lonze, MD, PhD, NYU Langone Health

Study record dates

Study Major Dates

• Study Start (Actual): March 20, 2022
• Primary Completion (Actual): May 16, 2023
• Study Completion (Estimated): March 14, 2024

Study Registration Dates

• First Submitted: December 22, 2020
• First Submitted That Met QC Criteria: December 22, 2020
• First Posted (Actual): December 23, 2020

Study Record Updates

• Last Update Posted (Actual): March 1, 2024
• Last Update Submitted That Met QC Criteria: February 29, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; RNA Virus Infections; Virus Diseases; Infections; Blood-Borne Infections; Communicable Diseases; Liver Diseases; Flaviviridae Infections; Hepatitis, Viral, Human; Hepatitis; Hepatitis C
• Other Study ID Numbers: 20-01386

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: This is a single center pilot study. Data will be available once published.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No